GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8.
Under the deal, GSK will receive a $320 million cash payment. The drugmaker also will collect a 1% royalty on any future U.S. sales of influenza, COVID-19 and related combination mRNA vaccines developed by BioNTech and Pfizer.
CureVac announced Aug. 7 it had reached agreements with BioNTech and Pfizer to resolve pending U.S. patent litigation tied to mRNA technology, resulting in a total payment of $740 million between the two drugmakers.
GSK said the settlement does not affect its ongoing patent enforcement actions against BioNTech and Pfizer in the U.S. and Europe, according to the Journal.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
